10-K: Tempus AI's 10-K Filing Reveals Strategic Focus on Intelligent Diagnostics and AI Applications

Tempus AI's 10-K filing highlights its commitment to precision medicine through intelligent diagnostics and the application of artificial intelligence in healthcare.

Summary

• Tempus AI's 10-K filing outlines the company's focus on creating Intelligent Diagnostics through AI in healthcare.
• The company's platform, comprising a technology platform and operating system, aims to unlock the power of precision medicine.
• Tempus has amassed a large library of clinical and molecular oncology data.
• The company's products are organized under three product lines: Genomics, Data, and AI Applications.
• The Genomics product line provides NGS diagnostics and pathology testing.
• The Data and Services product line facilitates drug discovery and development through Insights and Trials products.
• The AI Applications product line focuses on algorithmic diagnostics and clinical decision support tools.
• As of December 31, 2024, the company has signed contracts with a Remaining Total Contract Value (TCV) of more than $940.0 million, which includes approximately $300.0 million in additional potential future contractual opt-ins.
• For the year ended December 31, 2024, Net Revenue Retention for the Insights product was approximately 140% compared to the same cohort of customers for the period ended December 31, 2023.
• The company's clinical volume in oncology rose from approximately 31,000 samples sequenced in 2018 to approximately 350,000 samples in 2024.
• The company acquired Ambry Genetics Corporation in February 2025 to expand its data offerings and disease area coverage.
• As of December 31, 2024, the company had more than 2,400 employees.
• The company reported a net loss of $705.8 million for the year ended December 31, 2024.
• The company is subject to various regulations, including those related to medical devices, laboratory testing, and data privacy.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there's revenue growth and strategic acquisitions, the significant net loss and potential need for future capital raises temper the overall outlook.

Positives

• The company has a large and growing database of clinical and molecular data.
• The company has established strategic collaborations with major pharmaceutical companies.
• The company is expanding its product offerings and entering new disease areas.
• The company is experiencing growth in clinical volume and revenue.
• The company has a high net revenue retention rate for its Insights product.

Negatives

• The company has incurred significant losses since inception.
• The company's AI Applications product line is nascent.
• The company is subject to intense competition.
• The company's operating results may fluctuate significantly.
• The company is dependent on third-party payers for reimbursement.

Risks

• The company may not be able to achieve or maintain profitability.
• The company's products may not achieve sufficient commercial market acceptance.
• The company may need to raise additional capital in the future.
• The company's industry is subject to rapid change.
• The company is subject to stringent and evolving regulations.
• The company may be involved in intellectual property litigation.
• The company is dependent on key personnel.
• The company's information technology systems may be compromised.
• The company's dual class structure concentrates voting control.
• The company's stock price may be volatile.

Future Outlook

The company plans to continue investing in product innovation, customer acquisition, and technology to drive growth and expand its platform into new disease areas.

Industry Context

The announcement reflects the increasing trend of leveraging AI and data analytics in healthcare to personalize medicine and improve patient outcomes, positioning Tempus AI within the competitive landscape of precision diagnostics and data-driven drug discovery.

Comparison to Industry Standards

• Tempus AI competes with companies like Foundation Medicine, Caris Life Sciences, and Guardant Health in the genomic testing market.
• In the data and services market, Tempus AI competes with Flatiron Health and IQVIA.
• The company's clinical trial matching services compete with those offered by CROs like Fortrea and Syneos.
• The company's AI Applications products compete with algorithm-based diagnostics from Roche Holdings, Caris Life Sciences, and Guardant Health.
• The company's cardiology Algos compete with companies such as HeartFlow Inc. and Eko Devices, Inc.

Legal Proceedings

• On June 11, 2024, Guardant filed a complaint against us in the U.S. District Court for the District of Delaware alleging that the Tempus xF, Tempus xF+, Tempus xM Monitor and Tempus xM MRD products use liquid biopsy technology that infringes five Guardant U.S. patents.

Stakeholder Impact

• Shareholders may experience volatility in the stock price.
• Employees may benefit from the company's growth and expansion.
• Customers may benefit from the company's innovative products and services.
• Suppliers may benefit from the company's increased demand for their products.
• Creditors may be exposed to increased risk due to the company's debt obligations.

Next Steps

• Continue to work with NGS, our local MAC in Chicago, to maintain coverage of current assays, obtain coverage of new assays through engagement and reconsideration requests, and to continue various appeals when coverage is denied.
• Continue to work with our new MAC, Palmetto, which covers our tests when performed out of our newest lab in Raleigh, North Carolina, to get the technical assessment of our assays approved and coverage policy in place for reimbursement.
• Continue to seek FDA approval of additional assays.
• Continue to work with commercial payers to both get in network and get our assay approved and reimbursement at a higher rate than it currently is.

Key Dates